<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hypertensive Disorders in Pregnancy - National Guidelines</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
        MathJax = {
            tex: {
                inlineMath: [['$', '$'], ['\\(', '\\)']],
                displayMath: [['$$', '$$'], ['\\[', '\\]']],
                processEscapes: true,
                processEnvironments: true,
                tags: 'ams'
            },
            svg: { fontCache: 'global' },
            options: {
                skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
            }
        };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>

<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon">üè†</span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="05-preterm-labor-and-birth.html" class="nav-button">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 33%;"></div>
                        </div>
                        <span class="progress-text">Section 6 of 18</span>
                    </div>
                    <a href="07-medical-disorders-diabetes.html" class="nav-button">
                        <span class="nav-text">Next: Diabetes in Pregnancy</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">HYPERTENSIVE DISORDERS IN PREGNANCY</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">

                <!-- START: introduction -->
                <section id="introduction" class="content-section">
                    <h2>Introduction</h2>
                    <div class="content-card">
                        <p>Hypertensive disorders in pregnancy constitute one of the major direct causes of maternal and
                            perinatal morbidity and mortality.</p>

                        <h3>Epidemiology</h3>
                        <ul class="enhanced-list">
                            <li>Hypertensive disorders of pregnancy complicate up to 10% of pregnancies globally. They
                                account for 12% of the direct causes of maternal mortality which includes obstetric
                                hemorrhage (25%), puerperal sepsis (15%), unsafe abortion (13%) and obstructed labor
                                (8%).</li>
                            <li>Hypertensive disorders of pregnancy account for 26% of deaths in Latin America and the
                                Caribbean and 9% of deaths in Africa</li>
                            <li>Pre-eclampsia and eclampsia have the greatest impact on maternal and newborn morbidity
                                and mortality. Pre-eclampsia is a major contributor to prematurity.</li>
                            <li>Pre-eclampsia complicates 2% to 8% of all pregnancies, contributes to 15% of preterm
                                deliveries, and between 9% to 26% of maternal deaths globally.</li>
                            <li>Pre-eclampsia and eclampsia related deaths can be avoided if women received timely and
                                effective care, delivered according to evidence-based standards.</li>
                        </ul>

                        <h3>Definition</h3>
                        <p>Hypertension in pregnancy is defined as a systolic blood pressure greater than or equal to
                            140 mmHg and/or diastolic blood pressure greater than or equal to 90 mmHg measured on 2
                            occasions and at least 4 hours apart</p>
                    </div>
                </section>
                <!-- END: introduction -->

                <!-- START: classification -->
                <section id="classification" class="content-section">
                    <h2>Classification of hypertensive disorders of pregnancy</h2>
                    <div class="content-card">
                        <p>There are 4 manifestations of hypertension in pregnancy</p>
                        <ul class="enhanced-list">
                            <li><strong>Chronic hypertension</strong> (both essential and secondary hypertension):
                                Hypertension confirmed pre-conception or prior to 20 weeks gestation</li>
                            <li><strong>Gestational hypertension/Pregnancy induced hypertension:</strong> New onset
                                hypertension arising after 20 weeks gestation in the absence of proteinuria and other
                                systemic symptoms. It resolves generally within 3 months post-partum</li>
                            <li><strong>Pre-eclampsia/eclampsia:</strong> Pre-eclampsia is a multisystem disorder of
                                unknown etiology characterized by elevated BP of 140/90 mm Hg or more with proteinuria
                                after the 20th week of gestation in a previously normotensive and non-proteinuric woman.
                            </li>
                            <li><strong>Pre-eclampsia superimposed on chronic hypertension:</strong> Features of
                                pre-eclampsia developing in a woman who had hypertension prior to conception</li>
                        </ul>

                        <p>The International Society for the Study of Hypertension in pregnancy (ISSHP) in 2018
                            recommended inclusion of the following as part of the hypertension disease spectrum in
                            pregnancy</p>
                        <ul class="enhanced-list">
                            <li><strong>White coat hypertension:</strong> White-coat hypertension refers to elevated
                                office/clinic blood pressure ($\geq 140/90$ mm Hg), but normal blood pressure measured
                                at home or work ($<135 /85$ mm Hg); it is not an entirely benign condition and conveys
                                    an increased risk for Pre-eclampsia</li>
                            <li><strong>Masked hypertension:</strong> Masked hypertension is more difficult to diagnose.
                                Characterized by blood pressure that is normal at a clinic or office visit but elevated
                                at other times and is typically diagnosed by 24 -hour ambulatory BP monitoring (ABPM) or
                                automated home BP monitoring.</li>
                            <li><strong>Transient gestational hypertension:</strong> Transient gestational hypertension
                                arises in the second or third trimester. Usually detected in the clinic but settles with
                                repeated BP readings. It differs from white-coat hypertension that, by definition, must
                                be present from early pregnancy. It is associated with a 40% risk of developing true
                                gestational hypertension or Pre-eclampsia in the remainder of the pregnancy, a fact that
                                highlights the importance of carefully follow-up of such women.</li>
                        </ul>

                        <p>Additionally, the following findings are indicative of Pre- eclampsia:</p>
                        <ol>
                            <li>Proteinuria (i.e., $\geq 30$ mg/mol protein: creatinine ratio; $\geq 300$ mg/24 hour; or
                                $\geq 2+$ dipstick );</li>
                            <li>Evidence of other maternal organ dysfunction, including: acute kidney injury (creatinine
                                $\geq 90$ $\mu$mol/L; 1 mg/dL); liver involvement (elevated transaminases, e.g. alanine
                                aminotransferase or aspartate aminotransferase > 40 IU/L) with or without right upper
                                quadrant or epigastric abdominal pain; neurological complications (e.g. eclampsia,
                                altered mental status, blindness, stroke, clonus, severe headaches, and persistent
                                visual scotomata); or hematological complications (thrombocytopenia-platelet count <
                                    150000 / $\mu$L, disseminated intravascular coagulation, hemolysis);</li>
                            <li>Uteroplacental dysfunction (such as fetal growth restriction, abnormal umbilical artery
                                Doppler waveform analysis, or stillbirth).</li>
                        </ol>

                        <h3>Classification of pre-eclampsia</h3>
                        <p>The current consensus is that pre-eclampsia should be classified as follows:</p>
                        <ul class="enhanced-list">
                            <li>Pre-eclampsia without severe features</li>
                            <li>Pre-eclampsia with severe features</li>
                        </ul>

                        <p>Subclassification of Pre-eclampsia includes:</p>
                        <ol>
                            <li>Early-onset PE (with delivery at < 34+0 weeks of gestation);</li>
                            <li>Preterm PE (with delivery at < 37+0 weeks of gestation);</li>
                            <li>Late-onset PE (with delivery at $\geq$ 34+0 weeks of gestation);</li>
                            <li>Term PE (with delivery at $\geq$ 37+0 weeks of gestation).</li>
                        </ol>
                        <p>This sub-classification is not discrete but used to address maternal and perinatal morbidity/
                            mortality in relation to gestation.</p>
                    </div>
                </section>
                <!-- END: classification -->

                <!-- START: risk-factors -->
                <section id="risk-factors" class="content-section">
                    <h2>Risk factors</h2>
                    <div class="content-card">
                        <h3>Maternal-specific risk factors</h3>
                        <ul class="enhanced-list">
                            <li>Extremes of age (maternal age < 20 and> 35 years)</li>
                            <li>Black race: (In the United States, the incidence of Pre-eclampsia is 1.8% among white
                                women and 3% in African Americans).</li>
                            <li>Family history of Pre-eclampsia</li>
                            <li>Nulliparity (more common in primigravidae)</li>
                            <li>Pre-eclampsia in a previous pregnancy Change of male partner</li>
                            <li>Diabetes</li>
                            <li>Obesity: Body weight is strongly correlated with progressively increased risk, ranging
                                from 4.3% for women with a BMI < 20 kg/m to 13.3% in those with a BMI> 35 kg/m.</li>
                            <li>Chronic hypertension</li>
                            <li>Renal disease</li>
                            <li>Collagen vascular disease</li>
                            <li>Antiphospholipid syndrome</li>
                            <li>Periodontal disease</li>
                            <li>Vitamin D deficiency: literature suggests that maternal vitamin D deficiency may
                                increase the risk of Pre-eclampsia and fetal grown restriction.</li>
                            <li>Inherited thrombophilias</li>
                            <li>Inter-pregnancy interval of > 10 years</li>
                        </ul>

                        <h3>Pregnancy-associated risk factors</h3>
                        <ul class="enhanced-list">
                            <li>Chromosomal abnormalities</li>
                            <li>Hydatidiform mole</li>
                            <li>Multiple pregnancy: Incidence is increased in twin gestations but is unaffected by their
                                zygosity</li>
                            <li>In-vitro fertilization, oocyte donation or donor insemination</li>
                        </ul>
                    </div>
                </section>
                <!-- END: risk-factors -->

                <!-- START: prevention -->
                <section id="prevention" class="content-section">
                    <h2>Prevention of pre-eclampsia and its complications</h2>
                    <div class="content-card">
                        <ul class="enhanced-list">
                            <li>Preventive interventions may be started before 16 weeks gestation when most of the
                                physiologic transformation of the uterine spiral arteries occurs or even before
                                pregnancy</li>
                            <li>Pregnant women have been classified as "low" or "high" risk of pre-eclampsia by presence
                                or absence of one or more risk factors (family history, previous history of
                                pre-eclampsia, chronic diseases such as diabetes, kidney disease and hypertension)</li>
                            <li>There is strong evidence that low risk women who may have low dietary intake of calcium
                                (600 mg/day) may benefit from calcium supplementation of at least 1g/day, orally</li>
                            <li>Vitamin D may play a protective role against pre-eclampsia through beneficial effects on
                                immune modulation and vascular function</li>
                            <li>High risk women are recommended to take calcium supplementation of at least 1g/day if
                                intake is low</li>
                            <li>A screening guide for first trimester for pre- eclampsia using the following can be
                                offered:
                                <ul>
                                    <li>Mean arterial pressure</li>
                                    <li>Biomarkers - placental growth factor, pregnancy associated plasma protein A</li>
                                    <li>Uterine artery pulsatility index</li>
                                    <li>Combination of these above risk assessment tests</li>
                                </ul>
                            </li>
                        </ul>
                        <aside class="callout note" role="note">
                            <h4 class="callout-title"><span class="callout-icon">‚ÑπÔ∏è</span> NOTE</h4>
                            <p>With first- trimester screening and assessment for preterm PE, women identified at high
                                risk should receive aspirin prophylaxis commencing at 11 to 14+6 weeks of gestation at a
                                dose of ~150 mg to be taken every night until either 36 weeks of gestation, when
                                delivery occurs, or when PE is diagnosed.</p>
                        </aside>
                    </div>
                </section>
                <!-- END: prevention -->

                <!-- START: diagnosis-criteria -->
                <section id="diagnosis-criteria" class="content-section">
                    <h2>Diagnostic criteria of pre-eclampsia</h2>
                    <div class="content-card">
                        <h3>Pre-eclampsia with severe features</h3>
                        <ul class="enhanced-list">
                            <li>Systolic BP greater than or equal to 160 mm Hg and diastolic BP more than or equal to
                                110 mm Hg</li>
                            <li>Proteinuria equal to or greater than 3 gm per 24 hour urine collection or the equivalent
                                in a test strip</li>
                            <li>Serum creatinine > 1.2 mg/dl</li>
                            <li>Thrombocytopenia less than 150000/mm3</li>
                            <li>Lactate Dehydrogenase equal to or more than 600 IU</li>
                            <li>Elevated serum transaminase levels (ALT, AST)</li>
                            <li>Persistent headache</li>
                            <li>Visual disturbances-scotomas/blurring of vision</li>
                            <li>Right upper quadrant pain</li>
                            <li>Epigastric pain</li>
                            <li>Intrauterine growth restriction of the fetus</li>
                            <li>Oligohydramnios</li>
                            <li>Oliguria less than 500 ml in 24 hours</li>
                            <li>Pulmonary edema</li>
                        </ul>

                        <p>In the absence of proteinuria, new onset hypertension with the following may be diagnostic of
                            pre-eclampsia</p>
                        <div class="table-container">
                            <table class="content-table">
                                <tbody>
                                    <tr>
                                        <td><strong>Thrombocytopenia</strong></td>
                                        <td>Platelet count < 100,000/mm3</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Renal insufficiency</strong></td>
                                        <td>Serum creatinine concentration > 1.1 mg/dl or doubling of serum creatinine
                                            in absence of other renal disease</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Impaired liver function</strong></td>
                                        <td>Elevation of transaminase levels to more than twice the normal levels</td>
                                    </tr>
                                    <tr>
                                        <td colspan="2"><strong>Pulmonary edema</strong></td>
                                    </tr>
                                    <tr>
                                        <td><strong>Cerebral/visual symptoms</strong></td>
                                        <td>Severe headache, blurring of vision</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        <aside class="callout note" role="note">
                            <h4 class="callout-title"><span class="callout-icon">‚ÑπÔ∏è</span> NOTE</h4>
                            <p>Proteinuria is not mandatory for a diagnosis of pre-eclampsia<br>Some degree of edema is
                                normal in pregnancy. However, gradual or sudden swelling of the face, hands and legs is
                                strongly suggestive of pre-eclampsia.</p>
                        </aside>

                        <h3>Tabulation of laboratory testing based on level of health facility</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>Diagnostic test</th>
                                        <th>Level of care</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>CBC</td>
                                        <td>3-6</td>
                                    </tr>
                                    <tr>
                                        <td>U/E/Cs</td>
                                        <td>3-6</td>
                                    </tr>
                                    <tr>
                                        <td>LFTs</td>
                                        <td>3-6</td>
                                    </tr>
                                    <tr>
                                        <td>Urinalysis</td>
                                        <td>3-6</td>
                                    </tr>
                                    <tr>
                                        <td>Serum creatinine level</td>
                                        <td>3-6</td>
                                    </tr>
                                    <tr>
                                        <td>Obstetric U/S</td>
                                        <td>3-6</td>
                                    </tr>
                                    <tr>
                                        <td>CTG (where GBD >24 weeks)</td>
                                        <td>3-6</td>
                                    </tr>
                                    <tr>
                                        <td>Coagulation profile</td>
                                        <td>4-6</td>
                                    </tr>
                                    <tr>
                                        <td>FDPs</td>
                                        <td>5-6</td>
                                    </tr>
                                    <tr>
                                        <td>Uric acid</td>
                                        <td>5-6</td>
                                    </tr>
                                    <tr>
                                        <td>CT scan brain</td>
                                        <td>5-6</td>
                                    </tr>
                                    <tr>
                                        <td>Serum magnesium levels (in suspected toxicity)</td>
                                        <td>6</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Investigations for fetal assessment</h3>
                        <ul class="enhanced-list">
                            <li>Cardiotocograph (CTG) if greater than 24weeks gestation</li>
                            <li>Ultrasound scan for assessment of:
                                <ul>
                                    <li>Fetal growth</li>
                                    <li>Amniotic fluid volume (AFV) or deepest vertical pocket (DVP)</li>
                                    <li>Umbilical artery flow (Doppler)</li>
                                </ul>
                            </li>
                            <li>Follow-up to assess fetal growth velocity</li>
                        </ul>
                    </div>
                </section>
                <!-- END: diagnosis-criteria -->

                <!-- START: severe-complications -->
                <section id="severe-complications" class="content-section">
                    <h2>Severe complications of pre-eclampsia</h2>
                    <div class="content-card">
                        <ul class="enhanced-list">
                            <li>Eclampsia</li>
                            <li>HELLP syndrome</li>
                            <li>Cerebral hemorrhage</li>
                            <li>Posterior reversible encephalopathy syndrome (PRES)</li>
                            <li>Reversible Cerebral vaso-constriction Syndrome</li>
                            <li>Intra uterine growth restriction and fetal compromise</li>
                            <li>Renal failure</li>
                            <li>Placenta abruptio</li>
                        </ul>

                        <h3>Eclampsia</h3>
                        <p>Defined as occurrence of one or more generalized tonic clone seizures superimposed on
                            pre-eclampsia. Seizures may occur ante-partum, intra-partum or post-partum usually within 24
                            hours of delivery.</p>
                        <ul class="enhanced-list">
                            <li>Imminent eclampsia is defined in the Magpie trial as at least 2 of the following:
                                frontal headache, visual disturbances, altered sensorium, hyper-reflexia, epigastric
                                tenderness.</li>
                            <li>A common finding in eclampsia is posterior reversible leukoencephalopathy syndrome
                                (PRES). Vasogenic edema in the posterior cerebral circulation, a finding also seen in
                                hypertensive encephalopathy.</li>
                            <li>The hypertension associated with eclampsia and PRES is often less severe than in
                                nonpregnant hypertensive encephalopathy, and it is possible that the endothelial damage
                                associated with Pre-eclampsia predisposes to this syndrome even at lower blood pressure
                            </li>
                        </ul>

                        <h3>HELLP syndrome</h3>
                        <p>HELLP syndrome describes a constellation of Hemolysis (anemia with blood film evidence of
                            hemolysis), Elevated Liver enzymes showing hepatic dysfunction (transaminases greater than
                            twice the normal range), and Low Platelets (platelet count of less than 150,000/dl).</p>
                        <p>HELLP is associated with maternal mortality and severe morbidity including disseminated
                            intravascular coagulopathy, liver hematoma, liver failure, and renal failure</p>

                        <h3>Pulmonary edema</h3>
                        <p>Hypoalbuminemia leads to reduced oncotic pressure and relative intravascular volume depletion
                            with significant interstitial fluid. Women with Pre-eclampsia are thus much more vulnerable
                            to pulmonary edema, especially those with significant renal impairment. For this reason,
                            careful fluid management is critical in all women with Pre-eclampsia, and pulmonary edema
                            secondary to iatrogenic fluid overload is a cause of maternal mortality in Pre-eclampsia</p>
                    </div>
                </section>
                <!-- END: severe-complications -->

                <!-- START: treatment -->
                <section id="treatment" class="content-section">
                    <h2>Treatment of Patients with Pre-Eclampsia/Eclampsia</h2>
                    <div class="content-card">
                        <h3>General principles:</h3>
                        <ul class="enhanced-list">
                            <li><strong>BP control</strong>
                                <ul>
                                    <li>The goal is to lower BP to prevent cerebrovascular and cardiac complications
                                        while maintaining utero-placental blood flow.</li>
                                    <li>Antihypertensive treatment is indicated for diastolic blood pressure above 110
                                        mm Hg and systolic pressure above 160 mm Hg</li>
                                    <li>Patients with pre-eclampsia with severe features who have BP below 160/110 mm Hg
                                        may benefit from antihypertensive drugs because of the possibility of
                                        unpredictable acceleration of the disease and sudden increases in blood pressure
                                    </li>
                                    <li>The goal is to maintain diastolic blood pressure between 80 and 100 mm Hg and
                                        systolic pressure between 130 and 150 mm Hg. Target rate of lowering the acutely
                                        elevated BP</li>
                                    <li>First-line medications are labetalol 100 mg BD, given orally or IV; nifedipine
                                        20 mg OD, given orally or IV; or IV hydralazine 25 mg BD. (Atenolol, ACE
                                        inhibitors, ARBs, and diuretics should be avoided).</li>
                                </ul>
                            </li>
                        </ul>
                        <p>The goals of antenatal care in the presence of hypertension include control BP, recognize
                            Preeclampsia early, prevent eclampsia, and optimize birth for both the woman and her baby.
                        </p>

                        <h3>Moderately elevated BP</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>Aspect</th>
                                        <th>Considerations</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Context</td>
                                        <td>
                                            <ul>
                                                <li>Antihypertensive therapy halves the risk of developing severe
                                                    hypertension, but has no clear effect on other outcomes (e.g.
                                                    Preeclampsia, perinatal mortality)</li>
                                                <li>Concerns exist about the potential for decreased placental perfusion
                                                    from aggressive BP lowering that might jeopardize fetal well-being
                                                </li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Indications for drug therapy</td>
                                        <td>Consider drug therapy if:
                                            <ul>
                                                <li>Systolic BP is 140-160 mmHg and/or</li>
                                                <li>Diastolic BP is 90-100 mmHg and/or</li>
                                                <li>There are associated signs and symptoms of Pre-eclampsia</li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Target BP</td>
                                        <td>
                                            <ul>
                                                <li>There is no clear evidence about the optimal target BP for moderate
                                                    hypertension in pregnancy</li>
                                                <li>Lower end targets may be appropriate if there are comorbidities</li>
                                                <li>Consider individual circumstances</li>
                                                <li>Suggested targets: systolic BP less than 140 mmHg , diastolic BP
                                                    less than 90 mmHg</li>
                                            </ul>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Oral antihypertensive drug therapy</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>Drug</th>
                                        <th>Oral dose</th>
                                        <th>Adjust frequency and dose as clinically indicated</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>**Methyldopa</td>
                                        <td>250-500 mg</td>
                                        <td>Initially: 125-250 mg BD Up to: 500 mg QID Maximum: 2 g</td>
                                    </tr>
                                    <tr>
                                        <td>*Labetalol</td>
                                        <td>100-400 mg</td>
                                        <td>Initially: 100 mg BD Up to: 200-400 mg QID Maximum: 2.4 g</td>
                                    </tr>
                                    <tr>
                                        <td>*Hydralazine</td>
                                        <td>25-50 mg</td>
                                        <td>Initially: 25 mg BD Up to: 50-100 mg BD Maximum: 200 mg</td>
                                    </tr>
                                    <tr>
                                        <td>**Nifedipine (SR)</td>
                                        <td>20 mg</td>
                                        <td>Initially: 20-30 mg daily Up to: 60-120 mg daily Maximum: 120 mg</td>
                                    </tr>
                                    <tr>
                                        <td>*Nifedipine (immediate release)</td>
                                        <td>10-20 mg</td>
                                        <td>Initially: 10-20 mg BD Up to: 40 mg BD Maximum: 80 mg</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        <p><em>Footnote: *First line drug, ** Second line drug</em></p>

                        <h3>Management of severe acutely elevated BP</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>Aspect</th>
                                        <th>Considerations</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Context</td>
                                        <td>
                                            <ul>
                                                <li>The antihypertensive agent of choice for acute control has not been
                                                    established and initial therapy can be with one of a variety of
                                                    antihypertensive agents</li>
                                                <li>Persistent or refractory severe hypertension may require repeated
                                                    doses</li>
                                                <li>The concurrent administration of longer acting oral agents will
                                                    achieve a more sustained BP lowering effect</li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Indications for drug therapy</td>
                                        <td>Commence pharmacological treatment if:
                                            <ul>
                                                <li>sBP is greater than or equal to 160 mmHg and/or dBP is greater than
                                                    or equal to 100 mmHg</li>
                                                <li>sBP greater than or equal to 170 mmHg with or without dBP greater
                                                    than or equal to 110 mmHg is a medical emergency and requires urgent
                                                    treatment</li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Target BP</td>
                                        <td>
                                            <ul>
                                                <li>Target sBP range of <strong>130 to 150 mmHg</strong></li>
                                                <li>Target dBP range 80 to 90 mmHg</li>
                                                <li>Aim for gradual and sustained lowering of BP so blood flow to the
                                                    fetus is not compromised</li>
                                            </ul>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Control of seizures</h3>
                        <ul class="enhanced-list">
                            <li>The basic principles of airway, breathing, circulation (the ABCs) should always be
                                followed as a general principle of seizure management.</li>
                            <li>Active seizures should be treated with intravenous magnesium sulphate as a first-line
                                agent.</li>
                            <li>Prophylactic treatment with magnesium sulphate is indicated for all patients with
                                Preeclampsia with severe features</li>
                            <li>Magnesium levels, respiratory rate, reflexes, and urine output must be monitored to
                                detect magnesium toxicity. Magnesium sulphate is mostly excreted in the urine, and
                                therefore urine output needs to be closely monitored. If urine output falls below 20
                                mL/h, the magnesium infusion should be stopped.</li>
                            <li>There is a risk of seizures following delivery since up to 44% of eclampsia cases have
                                been reported to occur post-partum. This risk is especially elevated 48 hours
                                postpartum, but it can occur at any time up to 4 weeks after delivery.</li>
                            <li>For seizure refractory to magnesium sulphate therapy or with acute kidney injury,
                                benzodiazepines and/or phenytoin may be considered.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: treatment -->

                <!-- START: mgso4-regimen -->
                <section id="mgso4-regimen" class="content-section">
                    <h2>Magnesium Sulphate Preparation and Regimen</h2>
                    <div class="content-card">
                        <h3>MgSO4 dosing and monitoring checklist</h3>
                        <h4>Preparation of 4g 20% solution of magnesium sulfate (mgso4) from 50% ampule</h4>
                        <ul class="enhanced-list">
                            <li>Wash hands thoroughly with soap and running water or use 70% alcohol hand rub and air
                                dry.</li>
                            <li>Using a 20-mL syringe, draw 12 mL of sterile water for injection.</li>
                            <li>If 50% MgSO4. is available, add 8 mL of MgSO4 50% solution* to 12 mL of water for
                                injection to make 20 mL of 20% solution (4 g per 20 mL).</li>
                            <li>If the concentration is different, correctly mix 4 gm of MgSO4. * vial containing (1g/2
                                mL)</li>
                        </ul>

                        <h4>Calculation of the drug</h4>
                        <ul class="enhanced-list">
                            <li>x "% of Magnesium sulphate contains " x " gm in 100 ml</li>
                            <li>1 ampoule contains 50% of 2 ml Magnesium sulphate</li>
                            <li>1 ampoule contains 1 gm of Magnesium sulphate in 2 ml</li>
                            <li>4 ampoule provides 4 gm of Magnesium sulphate in 8 ml</li>
                            <li>To prepare 20% of 4 gm Magnesium sulphate, "y" ml of Normal saline (NS) must be added:
                                <ul>
                                    <li>20 gm/100 ml = 4 gm/(8 ml + "y" ml)</li>
                                    <li>8 + "y" = 20</li>
                                    <li>"y" = 12</li>
                                </ul>
                            </li>
                        </ul>

                        <h3>Mg SO 4 regimens include:</h3>
                        <p><strong>Zuspan regimen</strong> is a treatment regimen using Magnesium sulphate for the
                            treatment of eclampsia via the intravenous route. Magnesium sulphate <strong>4g</strong> is
                            given asIV bolus as initial dose. This is followed by intravenous infusion of Magnesium
                            sulphate at the rate of 1g/hour till 24 hours have elapsed after the last seizure</p>

                        <p><strong>Pritchard's regimen</strong> principally the intramuscular route</p>
                        <p><strong>Loading dose:</strong></p>
                        <p>Initially: 4 gm of 20% MgSO4 IV over not less than 3 minutes</p>
                        <ul class="enhanced-list">
                            <li>Take one 20 ml syringe</li>
                            <li>Draw 4 ampoules of Magnesium sulphate</li>
                            <li>Add 12 ml Normal saline</li>
                        </ul>
                        <p>Immediately followed by: 10 gm of 50% MgSO4 IM (5 gm in each buttock)</p>
                        <ul class="enhanced-list">
                            <li>Take two <strong>10 ml</strong> syringes</li>
                            <li>Draw 5 ampoules of MgSO4 in each syringe</li>
                            <li>Ad d 1 ml of 2% Lignocaine in each syringe</li>
                            <li>Give deep IM in each buttock</li>
                        </ul>
                        <p>If convulsion persists after 15 minutes: 2 gm of 50% MgSO4 IV bolus given over 5 minutes</p>
                        <ul class="enhanced-list">
                            <li>Take one 10 ml syringe</li>
                            <li>Draw 2 ampoules of Magnesium sulphate</li>
                        </ul>
                        <p><strong>b. Maintenance dose:</strong></p>
                        <ul class="enhanced-list">
                            <li>5 gm of 50% MgSO4 IM 4 hourly in alternate buttocks</li>
                            <li>Take one 10 ml syringe</li>
                            <li>Draw 5 ampoules of MgSO4</li>
                            <li>Add 1 ml of 2% Lignocaine in each syringe</li>
                            <li>Give deep IM 4 hourly in alternate buttocks</li>
                            <li>Continue for 24 hours after the last convulsion or delivery whichever is later.</li>
                        </ul>

                        <p><strong>Sibai regimen</strong> is an intravenous magnesium sulphate regimen for treatment of
                            eclampsia It was introduced by Sibai et al in 1990. Loading dose - 6g IV given over 20
                            minutes. Maintenance dose - <strong>2-3 g</strong> IV every hour</p>
                        <p><strong>VIMS</strong> single dose administered prior to referral single doses of 4 g diluted
                            50% Mgso4 intravenously, with simultaneous 4 g 50% MgSo4 intramuscularly</p>

                        <h3>Administration of loading dose of MgSO4</h3>
                        <ul class="enhanced-list">
                            <li>Establish an IV line using normal saline or Ringer's lactate solution.</li>
                            <li>Using a 20 mL syringe, draw 4 g of MgSO4 50% (8 mL)</li>
                            <li>Add 12 mL sterile water or saline to the same syringe to make a 20% solution</li>
                            <li>Give this 4 g MgSO4 20% solution IV over 5-20 minutes.</li>
                            <li>Using two 20 mL syringes, draw 5 g of MgSO4 50% (10 mL) in EACH syringe.</li>
                            <li>Add 1mL of 2% lignocaine to EACH of the two syringes.</li>
                            <li>Inject the drug from the 1st syringe deep IM injection into one buttock (5 g MgSO4)</li>
                            <li>Inject the drug from the 2nd syringe deep IM injection into the other buttock (5 g
                                MgSO4)</li>
                        </ul>

                        <h3>Monitoring for signs of toxicity</h3>
                        <ul class="enhanced-list">
                            <li>Count respiration rate for 1 minute every hour. The rate should be $\geq 16$.</li>
                            <li>Patella reflexes should be present. Check every hour: - Place one hand under woman's
                                knee and lift leg off bed. - Tap patellar tendon just below kneecap with a reflex
                                hammer.</li>
                            <li>Insert an indwelling urinary catheter and measure urinary output hourly. Output should
                                be $\geq 30$ ml/hour</li>
                        </ul>

                        <h3>Administration of maintenance dose of MgSO4</h3>
                        <p>Before repeating administration of MgSO4, check that:</p>
                        <ul class="enhanced-list">
                            <li>Respiratory rate is at least 16 per minute.</li>
                            <li>Patellar reflexes are present.</li>
                            <li>Urinary output is at least 30 mL per hour over 4 hours.</li>
                        </ul>
                        <p>Give 5 grams of MgSO4 50% solution, together with 1 mL of 2% lignocaine in the same syringe,
                            by deep IM injection into alternate buttocks (every 4 hours).</p>
                        <p>WITHHOLD or DELAY drug if:</p>
                        <ul class="enhanced-list">
                            <li>Respiratory rate falls below 16 per minute. -</li>
                            <li>Patellar reflexes are absent. -</li>
                            <li>Urinary output has fallen below 30 mL per hour over the preceding 4 hours.</li>
                        </ul>
                        <p>In case of respiratory arrest:</p>
                        <ul class="enhanced-list">
                            <li>Shout for help!</li>
                            <li>Assist ventilation with mask and bag.</li>
                            <li>Give calcium gluconate 1g (10 mL of 10% solution) IV slowly.</li>
                        </ul>

                        <h3>Monitoring Hourly for Magnesium Sulphate toxicity:</h3>
                        <p>Suspend or postpone use of Magnesium sulphate, if any of the following is present:</p>
                        <ul class="enhanced-list">
                            <li>Respiratory rate < 16/min (Respiratory depression)</li>
                            <li>Absent patellar reflex (Muscle paresis)</li>
                            <li>Urine output < 30 ml/hour in preceding 4 hours (Impaired renal function)</li>
                        </ul>
                        <aside class="callout note" role="note">
                            <h4 class="callout-title"><span class="callout-icon">‚ÑπÔ∏è</span> Note</h4>
                            <p>Loss of patellar reflex is the 1st sign of Magnesium toxicity.</p>
                        </aside>
                        <p>The therapeutic level of serum magnesium is 4-7 mEq/l. Serum levels of Magnesium toxicity:
                        </p>
                        <ul class="enhanced-list">
                            <li>8-12 mEq/l: Loss of patellar reflex, flushing, warmth, somnolence, slurred speech</li>
                            <li>15-17 mEq/l: Muscular paralysis, Respiratory difficulty</li>
                            <li>30-35 mEq/l: Cardiac arrest</li>
                        </ul>

                        <h3>Management of Magnesium Sulphate toxicity:</h3>
                        <p>If urine output < 30 ml/hour:</p>
                                <ul class="enhanced-list">
                                    <li>MgSO4 withheld</li>
                                    <li>IV Ringers lactate infusion 1 litre over 8 hours</li>
                                    <li>Monitor for pulmonary oedema</li>
                                </ul>
                                <p>If respiratory arrest occurs:</p>
                                <ul class="enhanced-list">
                                    <li>Perform assisted ventilation</li>
                                    <li>Antidote: Calcium gluconate 1 gm (10% of 10 ml) IV slowly over 10 minutes</li>
                                </ul>

                                <h3>Contraindication of Magnesium Sulphate:</h3>
                                <ul class="enhanced-list">
                                    <li>Myasthenia gravis</li>
                                    <li>Impaired renal function</li>
                                </ul>

                                <h3>Other Magnesium Sulphate regimens:</h3>
                                <ul class="enhanced-list">
                                    <li>High dose regimens (Loading dose > 10gm): Pritchard, Lucas</li>
                                    <li>Low dose regimens (Loading dose < 10 gm): Zuspan or Sibai, Suman sardesai <ul>
                                    <li>Loading dose: 4-6 gm IV over 15-20 minutes</li>
                                    <li>Maintenance dose: 1-2 gm/hr IV infusion</li>
                                </ul>
                                </li>
                                <li>Single dose regimen: VIMS regimen
                                    <ul>
                                        <li>Single doses of 4 g diluted 50% Mgso4 intravenously, with simultaneous 4 g
                                            50% MgSo4 intramuscularly.</li>
                                    </ul>
                                </li>
                                </ul>
                                <p>Note: Researches have found that the Zuspan regimen is up to 8 times less effective
                                    than the Pritchard regimen in preventing convulsions in severe pre-eclampsia and
                                    eclampsia. The 'VIMS' regimen can be used at First Referral Units, before shifting
                                    the patients to tertiary care centres. This approach has special implications in the
                                    developing countries, especially at the primary care level, where the standard
                                    obstetric care is not widely available.</p>

                                <h3>Phenytoin</h3>
                                <p>Phenytoin has been used successfully in eclamptic seizures, but cardiac monitoring is
                                    required due to associated bradycardia and hypotension.</p>
                                <p>Central anticonvulsant effect of phenytoin is by stabilizing neuronal activity by
                                    decreasing the ion flux across depolarizing membranes.</p>
                                <p>Some benefits to using phenytoin are:</p>
                                <ul class="enhanced-list">
                                    <li>It can be continued orally for several days until the risk of eclamptic seizures
                                        has subsided,</li>
                                    <li>It has established therapeutic levels that are easily tested,</li>
                                    <li>It has no known neonatal adverse effects are associated with short-term usage.
                                    </li>
                                </ul>
                                <p>Dosage: 10 mg/kg loading dose infused IV no faster than 50 mg/min, followed by
                                    maintenance dose started 2 hours later at 5 mg/kg</p>
                    </div>
                </section>
                <!-- END: mgso4-regimen -->

                <!-- START: fluid-management-and-delivery -->
                <section id="fluid-management-and-delivery" class="content-section">
                    <h2>Fluid management and Delivery</h2>
                    <div class="content-card">
                        <h3>Fluid management</h3>
                        <ul class="enhanced-list">
                            <li>Despite the peripheral edema, patients with Pre-eclampsia are intravascularly volume
                                depleted with high peripheral vascular resistance. Diuretics should be avoided.</li>
                            <li>Aggressive volume resuscitation may lead to pulmonary edema. Pulmonary edema occurs most
                                frequently 48-72hours post-partum, probably due to mobilization of extravascular fluid.
                            </li>
                            <li>Volume expansion has no demonstrated benefit, patients should be fluid restricted when
                                possible, at least until the period of postpartum diuresis. Total fluids should
                                generally be limited to 80 mL/h or 1 mL/kg/h.</li>
                            <li>Careful measurement of fluid input and output is advisable, particularly in the
                                immediate postpartum period. Many patients will have a brief (up to 6 h) period of
                                oliguria following delivery; this should be anticipated and not overcorrected.</li>
                            <li>If fluids are required, preferably use Ringer's Lactate or Normal saline at a rate of 80
                                mls/hour or 1 ml/kg/hr. Avoid using Dextrose or Dextrose- Saline infusion</li>
                        </ul>

                        <h3>Delivery</h3>
                        <ul class="enhanced-list">
                            <li>Delivery is the definitive treatment for antepartum Pre-eclampsia.</li>
                            <li>Patients with mild Pre-eclampsia are often induced after 37 weeks' gestation. Prior to
                                this, the immature fetus is treated with expectant management with corticosteroids to
                                accelerate lung maturity in preparation for early delivery.</li>
                            <li>In patients with severe Pre-eclampsia, induction of delivery should be considered after
                                34 weeks' gestation. In these cases, the severity of disease must be weighed against the
                                risks of prematurity.</li>
                            <li>Eclampsia is common after delivery and has occurred up to 6 weeks after delivery.
                                Patients at risk for eclampsia should be carefully monitored postpartum.</li>
                        </ul>

                        <h3>Indications for delivery:</h3>
                        <p>Non-Reassuring Fetal Status, severe fetal growth restriction, gestational age>/=37weeks,
                            eclampsia, placental abruption, acute pulmonary edema, deteriorating platelet count,
                            persistent neurological symptoms, persistent epigastric pain, nausea and vomiting.</p>

                        <h3>Medication</h3>
                        <ul class="enhanced-list">
                            <li>Magnesium sulphate is the first-line treatment of prevention of primary and recurrent
                                eclamptic seizures.</li>
                            <li>Evidence has also shown that magnesium sulphate has a neuroprotective role in preventing
                                cerebral palsy following preterm birth</li>
                            <li>For eclamptic seizures refractory to magnesium sulphate, Diazepam and phenytoin may be
                                used as second-line agents</li>
                            <li>In the setting of severe hypertension (systolic BP, >160 mm Hg; diastolic BP, >110 mm
                                Hg), antihypertensive treatment is recommended. Antihypertensive treatment decreases the
                                incidence of cerebrovascular problems but does not alter the progression of
                                Pre-eclampsia.</li>
                        </ul>

                        <figure>
                            <img src="../assets/images/2025_11_24_1f5d3abc0b734f89226ag-151-1.jpg"
                                alt="Figure 23: Management of pre-eclampsia and hellp syndrome at less than 34 weeks"
                                class="content-image">
                            <figcaption>Figure 23: Management of pre-eclampsia and hellp syndrome at less than 34 weeks
                            </figcaption>
                        </figure>

                        <h3>Loading dose MgSO4</h3>
                        <p>4g IV over 20 mins via controlled infusion</p>
                        <p>If seizures occur/ongoing while preparing MgSO4/re-occurs while giving MgSo4:</p>
                        <ul class="enhanced-list">
                            <li>Diazepam 5-10 mg IV at rate of 2-5 mg/min (max 10 mg)</li>
                            <li>Clonazepam 1-2 mg IV over 2-5 mins</li>
                            <li>Midazolam 5-10 mg IV over 2-5 mins/IM</li>
                        </ul>

                        <h3>Maintenance dose of MgSo4</h3>
                        <p>1g per hour via controlled infusion for 24 hours after birth or after last convulsion then
                            review requirement</p>
                        <p>If impaired renal function</p>
                        <p>Reduce maintenance dose to 0.5g per hour and consider serum monitoring</p>

                        <h3>Monitor:</h3>
                        <ul class="enhanced-list">
                            <li>BP and pulse every 5minutes until stable then every 30 mins</li>
                            <li>Respiratory Rate and patellar reflexes hourly</li>
                            <li>Temperature 2hourly</li>
                            <li>Urine output hourly</li>
                            <li>Strict fluid balance monitoring</li>
                            <li>Therapeutic serum magnesium level 1.7 to 3.5 mmol/liter</li>
                            <li>Stop infusion if toxicity is clinically suspected</li>
                        </ul>

                        <h3>Review with consultant if:</h3>
                        <p>urine output < 80mls in 4hours</p>
                                <p>Deep tendon reflexes absent and RR < 12 breaths/min</p>

                                        <h3>TREAT HYPERTENSION</h3>
                                        <p>If Systolic BP >/= 160 mmHg or diastolic BP >/= 100 mmHg</p>
                                        <p>Aim to reduce Systolic BP to 130 - 150 mmHg and diastolic BP to 80 - 100 mmHg
                                        </p>
                                        <p>Avoid maternal hypotension</p>
                                        <p>Monitor fetal heart rate with continuous CTG</p>

                                        <h3>ANTIHYPERTENSIVE MEDICATION</h3>
                                        <p>PO Nifedipine 10 - 20 mg, repeat after 45 minutes, max 80 mg</p>
                                        <p>Hydralazine: 5 - 10 mg IV over 3 to 10 mins . Repeated doses 5 mg Iv every 20
                                            mins if required. Max dose 30 mg . it may also be given as a 10-20 mg IV
                                            infusion and titrated against BP response</p>
                                        <p>Labetalol: Initially 20 mg IV bolus over 2 mins . Repeated doses 40 - 80 mg
                                            IV every 10 mins to max of 300 mg if required</p>

                                        <h3>BIRTH</h3>
                                        <p>Continue close fetal monitoring</p>
                                        <p>Stabilize mother prior to birth</p>
                                        <p>Ergometrine should not be used in both pre-eclampsia and eclampsia</p>
                                        <p>Consider prophylaxis for venous thromboembolism</p>

                                        <h3>Pre Eclampsia/Eclampsia</h3>
                                        <h4>Administering Magnesium Sulfate</h4>
                                        <figure>
                                            <img src="../assets/images/2025_11_24_1f5d3abc0b734f89226ag-153-1.jpg"
                                                alt="Administering Magnesium Sulfate" class="content-image">
                                        </figure>

                                        <h3>EVALUATION AND MANAGEMENT OF WOMEN AT RISK OF PREECLAMPSIA RECURENCE</h3>
                                        <div class="table-container">
                                            <table class="content-table">
                                                <thead>
                                                    <tr>
                                                        <th>Risk Level</th>
                                                        <th>Risk Factors</th>
                                                        <th>Recommendation</th>
                                                    </tr>
                                                </thead>
                                                <tbody>
                                                    <tr>
                                                        <td>High ‚Ä°</td>
                                                        <td>History of Pre-eclampsia, especially when accompanied by an
                                                            adverse outcome, Multifetal gestation, Chronic hypertension,
                                                            Type 1 or 2 diabetes, Renal disease, Autoimmune disease
                                                            (systemic lupus erythematous, antiphospholipid syndrome)
                                                        </td>
                                                        <td>Recommend low-dose aspirin if the patient has $\geq$ 1 of
                                                            these highrisk factors</td>
                                                    </tr>
                                                    <tr>
                                                        <td>Moderate ‚Ä°</td>
                                                        <td>Nulliparity, Obesity (body mass index >30 kg/m¬≤), Family
                                                            history of Pre-eclampsia (mother or sister), Socio
                                                            demographic characteristics (African American race, low
                                                            socioeconomic status), Age $\geq$ 35 years, Personal history
                                                            factors (e.g., low birthweight or small for gestational age,
                                                            previous adverse pregnancy outcome, >10-year pregnancy
                                                            interval)</td>
                                                        <td>Consider low-dose aspirin if the patient has several of
                                                            these moderate-risk factors¬ß</td>
                                                    </tr>
                                                    <tr>
                                                        <td>Low</td>
                                                        <td>Previous uncomplicated full-term delivery</td>
                                                        <td>Do not recommend low-dose asprin</td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                        </div>
                    </div>
                </section>
                <!-- END: fluid-management-and-delivery -->

            </main>

            <!-- Bottom Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon">üè†</span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="05-preterm-labor-and-birth.html" class="nav-button">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 33%;"></div>
                        </div>
                        <span class="progress-text">Section 6 of 18</span>
                    </div>
                    <a href="07-medical-disorders-diabetes.html" class="nav-button">
                        <span class="nav-text">Next: Diabetes in Pregnancy</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>

</html>